S. Murray

R. Wirtz, E. Hahn, W. Brueckl, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.

G. Lazaridis, D. Rontogianni, K. Papadopoulou, 2018, American journal of cancer research.

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraf ﬁ n-Embedded Tissue of Human Lung Cancer

B. Bellosillo, I. Kern, I. Rouquette, 2020 .

Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.

M. Pai, M. Hoelscher, R. Dawson, 2011, American journal of respiratory and critical care medicine.

Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.

M. Dimopoulos, E. Patsouris, E. Patsouris, 2008, Anticancer research.

Improving tumour targeting and decreasing normal tissue uptake by optimizing the stoichiometry of a two‐step biotinylated‐antibody/streptavidin‐based targeting strategy: Studies in a nude mouse xenograft model

A. Maraveyas, S. Murray, A. Epenetos, 1998, International journal of cancer.

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data

Kim W. Lowe, J. Tímár, J. Trojan, 2016, Biomarkers in medicine.

Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.

M. Ladanyi, M. Berger, R. Motzer, 2022, JCO precision oncology.

Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.

C. Papadimitriou, H. Linardou, D. Bafaloukos, 2011, Current medicinal chemistry.

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.

M. Broggini, A. Psyrri, M. Milella, 2021, ESMO open.

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

R. Motzer, M. Voss, E. Reznik, 2021, Molecular Cancer Research.

Guideline on the requirements of external quality assessment programs in molecular pathology

A. Marchetti, G. Botti, E. Schuuring, 2012, Virchows Archiv.

Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer

D. Roukos, S. Murray, E. Briasoulis, 2007, Cancer biology & therapy.

Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

G. Fountzilas, A. Nikolaou, H. Linardou, 2011, Journal of oncology.

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Issa J. Dahabreh, I. Dahabreh, P. Kosmidis, 2009, Nature Reviews Clinical Oncology.

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

M Dietel, M. Dietel, K. Kerr, 2014, British Journal of Cancer.

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

E. Stathopoulos, A. Voutsina, S. Murray, 2007, British Journal of Cancer.

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database

Issa J Dahabreh, I. Dahabreh, P. Kosmidis, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias.

E. Hatzimichael, S. Murray, E. Briasoulis, 2013, American journal of blood research.

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

R. Motzer, V. Reuter, J. Chaim, 2020, Cancer.

All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer.

I. Dahabreh, P. Kosmidis, G. Mountzios, 2011, Cancer treatment reviews.

E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy

S. Murray, I. Sainis, E. Briasoulis, 2019, In Vivo.

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.

I. Dahabreh, H. Linardou, D. Bafaloukos, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.

G. Fountzilas, D. Pectasides, H. Linardou, 2006, Lung cancer.

Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis.

I. Dahabreh, S. Murray, 2011, Cancer Epidemiology.

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

F. Siannis, I. Dahabreh, P. Kosmidis, 2009, Clinical Cancer Research.

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

B. Bellosillo, I. Kern, I. Rouquette, 2019, The Journal of molecular diagnostics : JMD.

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

G. Fountzilas, P. Kosmidis, S. Murray, 2012, Journal of experimental & clinical cancer research : CR.

Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.

G. Fountzilas, D. Pectasides, S. Murray, 2007, Anticancer research.

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma

R. Motzer, P. Russo, A. Hakimi, 2021, Clinical Cancer Research.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

J. Forbes, F. Cavalli, R. Gelber, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Suggestions, Opinions and Recommendations for the Diagnosis, Management, Treatment and Surveillance of Lung Cancer

J. Dahabreh, S. Murray, C. Kosmas, 2011 .

TP53 Arg72Pro Polymorphism and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis

I. Dahabreh, H. Linardou, S. Murray, 2010, Cancer Epidemiology, Biomarkers & Prevention.

TP 53 Arg 72 Pro Polymorphism and Colorectal Cancer Risk : A Systematic Review and Meta-Analysis

I. Dahabreh, H. Linardou, S. Murray, 2010 .

HLA Class II Alleles and the Presence of Circulating Epstein-Barr Virus DNA in Greek Patients with Nasopharyngeal Carcinoma

T. Economopoulos, G. Fountzilas, A. Nikolaou, 2008, Strahlentherapie und Onkologie.

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

F. Siannis, I. Dahabreh, G. Fountzilas, 2008, The oncologist.

Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.

I. Adamakis, D. Pectasides, S. Murray, 2012, Pharmacogenomics.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

R. Plummer, M. Ranson, J. Soria, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-cancer therapeutic antibodies

H. Linardou, S. Murray, 2002 .

Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature.

M. Dimopoulos, G. Mountzios, C. Papadimitriou, 2010, Mutation research.

Somatic mutations of adenomatous polyposis coli gene and nuclear b‐catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication

M. Dimopoulos, E. Patsouris, E. Kastritis, 2009, International journal of cancer.

A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma.

A. Hakimi, R. Motzer, M. Voss, 2021 .

Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.

P. Russo, O. Akin, R. Motzer, 2022, European urology.

EGFR mutations and response to gefitinib or erlotinib: A meta-analysis based on a comprehensive EGFR somatic mutation database (www.egfr-mutations.org)

I. Dahabreh, P. Kosmidis, H. Linardou, 2008 .

723PGenotyping and mRNA profiling reveal actionable targets in biliary tract cancers

G. Lazaridis, D. Rontogianni, K. Papadopoulou, 2017 .

EvaluationoftheXpertMTB/RIFAssayfortheDiagnosisof Pulmonary Tuberculosis in a High HIV Prevalence Setting

M. Pai, M. Hoelscher, R. Dawson, 2011 .

a high HIV prevalence setting

M. Pai, M. Hoelscher, R. Dawson, 2011 .

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

F. Siannis, I. Dahabreh, P. Kosmidis, 2009, Clinical Cancer Research.